Biotech News
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection – – Exercised 40% U.S. Profit-Share option for the HSV helicase primase inhibitor program – – Received first $75 million collaboration extension fee from Gilead; cash runway projected into 2029 –
